Solithromycin

Chemical structure of Solithromycin

Solithromycin is a novel macrolide antibiotic that belongs to the ketolide class. It is designed to treat bacterial infections, particularly those caused by macrolide-resistant strains. Solithromycin is known for its broad-spectrum activity and is being investigated for its potential use in treating community-acquired bacterial pneumonia (CABP) and other infections.

Mechanism of Action

Solithromycin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby blocking the translocation of peptides. This action is similar to other macrolides, but solithromycin has additional binding sites that enhance its activity against resistant strains.

Clinical Uses

Solithromycin is primarily being developed for the treatment of community-acquired bacterial pneumonia. It has shown effectiveness against a variety of pathogens, including:

• Streptococcus pneumoniae
• Haemophilus influenzae
• Moraxella catarrhalis
• Mycoplasma pneumoniae
• Chlamydophila pneumoniae

Pharmacokinetics

Solithromycin is available in both oral and intravenous formulations. It is well absorbed when taken orally and has a long half-life, allowing for once-daily dosing. The drug is metabolized in the liver and excreted primarily in the feces.

Side Effects

Common side effects of solithromycin include:

• Gastrointestinal disturbances such as nausea and diarrhea
• Headache
• Dizziness

Serious side effects are rare but may include liver toxicity and allergic reactions.

Development and Approval

Solithromycin was developed by Cempra Inc., and it has undergone several clinical trials to assess its safety and efficacy. As of the latest updates, it is still under review by regulatory agencies for approval in various regions.

Related Pages

• Macrolide antibiotics
• Antibiotic resistance
• Community-acquired pneumonia